Table 2.
Results of immunohistochemistry for current and previously reported cases
| Antigen | Results for current cases | Results for previously reported cases |
|---|---|---|
| S-100 | 8/8 positive (strong, diffuse, nuclear and cytoplasmic) | 13/13 positive, with 11 described as strong and/or diffuse |
| EMA | 7/8 positive in perineurium-derived capsular cells surrounding tumor nodules | 6/7 positive in perineurium-derived capsular cells surrounding tumor nodules; 1/7 also positive in Antoni A areas |
| NFP | 5/8 positive among isolated peripheral and central cells | 4/6 focally, mainly, or rarely positive at periphery and/or within septa; 1/6 positive among residual axons within tumor nodules |
| CD34 | NP | 3/4 positive at periphery of some tumor nodules, 1/4 focally positive |
| GFAP | NP | 1/2 positive in perineurium and some tumor cells |
| vimentin | NP | 2/3 positive |
| CD56 | NP | 1/1 positive in tumor and perineurium |
| CD57 | NP | 2/2 positive |
| CD68 | NP | 1/1 “variably” positive |
| CD117 | NP | 2/2 positive (focally, among mast cells) |
| SOX10 | NP | 1/1 positive (strong and diffuse) |
| laminin | NP | 1/1 positive |
| AE1/AE3 | NP | 0/2 positive |
| SMA | NP | 0/2 positive |
| desmin | NP | 0/1 positive |
| calponin | NP | 0/1 positive |
| Factor XIIIa | NP | 0/1 positive |
| Bcl-2 | NP | 0/1 positive |
| SMARCB1 | NP | 1/1 positive (strong) |
| Ki-67 proliferation index | NP | 3/3 low (“<4–5%,” “rare,” or “mild”) |
NP not performed